These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38602408)

  • 1. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
    Hoenigl M; Arastehfar A; Arendrup MC; Brüggemann R; Carvalho A; Chiller T; Chen S; Egger M; Feys S; Gangneux J-P; Gold JAW; Groll AH; Heylen J; Jenks JD; Krause R; Lagrou K; Lamoth F; Prattes J; Sedik S; Wauters J; Wiederhold NP; Thompson GR
    Clin Microbiol Rev; 2024 Jun; 37(2):e0007423. PubMed ID: 38602408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Issues in Antifungal Resistance.
    Perfect JR; Ghannoum M
    Infect Dis Clin North Am; 2020 Dec; 34(4):921-943. PubMed ID: 33131575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative therapies for invasive fungal infections in preclinical and clinical development.
    Yu Y; Albrecht K; Groll J; Beilhack A
    Expert Opin Investig Drugs; 2020 Sep; 29(9):961-971. PubMed ID: 32662681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antifungal arsenal: alternative drugs and future targets.
    Wiederhold NP
    Int J Antimicrob Agents; 2018 Mar; 51(3):333-339. PubMed ID: 28890395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
    Hoenigl M; Sprute R; Egger M; Arastehfar A; Cornely OA; Krause R; Lass-Flörl C; Prattes J; Spec A; Thompson GR; Wiederhold N; Jenks JD
    Drugs; 2021 Oct; 81(15):1703-1729. PubMed ID: 34626339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.
    Parente-Rocha JA; Bailão AM; Amaral AC; Taborda CP; Paccez JD; Borges CL; Pereira M
    Mediators Inflamm; 2017; 2017():9870679. PubMed ID: 28694566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
    Rogers TR; Verweij PE; Castanheira M; Dannaoui E; White PL; Arendrup MC;
    J Antimicrob Chemother; 2022 Jul; 77(8):2053-2073. PubMed ID: 35703391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal drug resistance: evolution, mechanisms and impact.
    Revie NM; Iyer KR; Robbins N; Cowen LE
    Curr Opin Microbiol; 2018 Oct; 45():70-76. PubMed ID: 29547801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
    Lamoth F; Lewis RE; Kontoyiannis DP
    Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole: a new broad-spectrum antifungal agent.
    Kwon DS; Mylonakis E
    Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Diagnostics and Therapeutics for Invasive Fungal Infections.
    Friedman DZP; Schwartz IS
    Infect Dis Clin North Am; 2023 Sep; 37(3):593-616. PubMed ID: 37532392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial strategies for combating invasive fungal infections.
    Spitzer M; Robbins N; Wright GD
    Virulence; 2017 Feb; 8(2):169-185. PubMed ID: 27268286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungals discovery: an insight into new strategies to combat antifungal resistance.
    Fuentefria AM; Pippi B; Dalla Lana DF; Donato KK; de Andrade SF
    Lett Appl Microbiol; 2018 Jan; 66(1):2-13. PubMed ID: 29112282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in antifungal pharmacology.
    Lewis RE
    Mayo Clin Proc; 2011 Aug; 86(8):805-17. PubMed ID: 21803962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.
    Lamoth F; Damonti L; Alexander BD
    J Clin Microbiol; 2016 Jun; 54(6):1638-1640. PubMed ID: 27008871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.
    Gamaletsou MN; Walsh TJ; Sipsas NV
    Turk J Haematol; 2018 Mar; 35(1):1-11. PubMed ID: 29391334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
    Neoh CF; Chen SC; Lanternier F; Tio SY; Halliday CL; Kidd SE; Kong DCM; Meyer W; Hoenigl M; Slavin MA
    Clin Microbiol Rev; 2024 Jun; 37(2):e0000423. PubMed ID: 38551323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
    Bassetti M; Vena A; Bouza E; Peghin M; Muñoz P; Righi E; Pea F; Lackner M; Lass-Flörl C
    Clin Microbiol Infect; 2020 Aug; 26(8):1024-1033. PubMed ID: 32120042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How urgent is the need for new antifungals?
    Stewart AG; Paterson DL
    Expert Opin Pharmacother; 2021 Oct; 22(14):1857-1870. PubMed ID: 34231434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.